IsletRegen

IsletRegen is a biotechnology company focused on developing regenerative medicine therapies for the treatment of Type 1 diabetes. The company leverages a proprietary platform designed to regenerate functional pancreatic islet cells, aiming to restore endogenous insulin production in patients. By focusing on the underlying cellular deficiency of the disease, IsletRegen seeks to provide a long-term alternative to exogenous insulin therapy. Their approach combines advanced cell biology with regenerative techniques to create a sustainable source of insulin-producing cells. The company is currently in the pre-clinical stage, advancing its lead programs toward regulatory filings.